nach oben

Erschienen in:

26.04.2021 | CME

Einheitliche Klassifikation des pachychorioidalen Krankheitsspektrums

Erschienen in: Die Ophthalmologie | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die pachychorioidalen Erkrankungen sind alle durch eine Verdickung der Aderhaut gekennzeichnet. Die Gruppe umfasst die folgenden Krankheitsgruppen: pachychorioidale Pigmentepitheliopathie (PPE), Chorioretinopathia centralis serosa (CCS), pachychorioidale Neovaskulopathie (PNV), polypoidale chorioidale Vaskulopathie (PCV)/aneurysmatische chorioidale Neovaskularisation Typ 1 (ACNV‑1), fokale chorioidale Exkavation (FCE) und peripapilläres pachychorioidales Syndrom (PPS). Wenn bei verdickter Aderhaut zusätzlich eine Veränderung des retinalen Pigmentepithels vorliegt, lautet die Diagnose PPE; wenn die verdickte Aderhaut von subretinaler Flüssigkeit begleitet ist, lautet die Diagnose CCS; wenn eine chorioidale Neovaskularisation vorliegt, lautet die Diagnose PNV; wenn sie von Aneurysmen begleitet ist, lautet die Diagnose ACNV‑1. PPE, CCS, PNV und ACNV‑1 wurden als unabhängige Krankheitsentitäten angesehen, lassen sich aber als 4 Formen einer einzigen Krankheitsfamilie, der „pachychorioidalen Makulaerkrankung“, klassifizieren.

Ryan SJ (2006) Retina, 4. Aufl. Bd. 1. Elsevier Mosby, Philadelphia

Usui S, Ikuno Y, Akiba M, Maruko I, Sekiryu T, Nishida K, Iida T (2012) Circadian changes in subfoveal choroidal thickness and the relationship with circulatory factors in healthy subjects. Invest Ophthalmol Vis Sci 53:2300–2307PubMedCrossRef

Warrow DJ, Hoang QV, Freund KB (2013) Pachychoroid pigment epitheliopathy. Retina 33:1659–1672PubMedCrossRef

Dansingani KK, Balaratnasingam C, Naysan J, Freund KB (2016) En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. Retina 36:499–516PubMedCrossRef

Cheung CMG, Lee WK, Koizumi H et al (2019) Pachychoroid disease. Eye (Lond) 33:14–33CrossRef

Ruiz-Medrano J, Flores-Moreno I, Peña-García P, Montero JA, Duker JS, Ruiz-Moreno JM (2014) Macular choroidal thickness profile in a healthy population measured by swept-source optical coherence tomography. Invest Ophthalmol Vis Sci 55:3532–3542PubMedCrossRef

Siedlecki J, Schworm B, Priglinger SG (2019) The pachychoroid disease spectrum-and the need for a uniform classification system. Ophthalmol Retina 3:1013–1015PubMedCrossRef

Ikuno Y, Kawaguchi K, Nouchi T, Yasuno Y (2010) Choroidal thickness in healthy Japanese subjects. Invest Ophthalmol Vis Sci 51:2173–2176PubMedCrossRef

Coskun E, Okumus S, Gürler B et al (2014) Choroidal thickness in healthy Turkish subjects. Turk J Med Sci 44:56–61PubMedCrossRef

10.

Kim JH, Kang SW, Kim JR, Kim SJ (2013) Variability of subfoveal choroidal thickness measurements in patients with age-related macular degeneration and central serous chorioretinopathy. Eye (Lond) 27:809–815CrossRef

11.

Spaide RF, Koizumi H, Pozzoni MC (2008) Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 146:496–500PubMedCrossRef

12.

Ferrara D, Mohler KJ, Waheed N et al (2014) En face enhanced-depth swept-source optical coherence tomography features of chronic central serous chorioretinopathy. Ophthalmology 121:719–726PubMedCrossRef

13.

Yang L, Jonas JB, Wei W (2013) Choroidal vessel diameter in central serous chorioretinopathy. Acta Ophthalmol 91:358–362CrossRef

14.

Azar G, Wolff B, Mauget-Faÿsse M, Rispoli M, Savastano MC, Lumbroso B (2017) Pachychoroid neovasculopathy: aspect on optical coherence tomography angiography. Acta Ophthalmol 95:421–427PubMedCrossRef

15.

Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA (1995) Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 15:100–110PubMedCrossRef

16.

Yannuzzi LA (2011) Indocyanine green angiography: a perspective on use in the clinical setting. Am J Ophthalmol 151:745–751PubMedCrossRef

17.

Ersoz MG, Arf S, Hocaoglu M, Sayman Muslubas I, Karacorlu M (2018) Indocyanine green angiography of pachychoroid pigment epitheliopathy. Retina 38:1668–1674PubMedCrossRef

18.

Nicholson B, Noble J, Forooghian F, Meyerle C (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58:103126CrossRef

19.

Gal-Or O, Dansingani KK, Sebrow D, Dolz-Marco R, Freund KB (2018) Inner choroidal flow signal attenuation in pachychoroid disease: optical coherence tomography angiography. Retina 38:1984–1992PubMedCrossRef

20.

Venkatesh P, Takkar B, Temkar S (2018) Clinical manifestations of pachychoroid may be secondary to pachysclera and increased scleral rigidity. Med Hypotheses 113:72–73PubMedCrossRef

21.

Lehmann M, Bousquet E, Beydoun T, Behar-Cohen F (2015) Pachychoroid: an inherited condition? Retina 35:10–16PubMedCrossRef

22.

Shah VS, Manayath FGJ, Saravanan VR, Shah PK, Prabhu V, Karandikar SS, Kalpana N (2017) PCV and CSR: diseases of the same spectrum?

23.

Dansingani KK, Balaratnasingam C, Klufas MA, Sarraf D, Freund KB (2015) Optical coherence tomography angiography of shallow irregular pigment epithelial detachments in pachychoroid spectrum disease. Am J Ophthalmol 160:1243–54.e2PubMedCrossRef

24.

Pang CE, Freund KB (2014) Pachychoroid pigment epitheliopathy may masquerade as acute retinal pigment epitheliitis. Invest Ophthalmol Vis Sci 55:5252PubMedCrossRef

25.

Wykrota A, Löw U, Fries FF, Seitz B, Abdin AD (2020) Unilaterale makuläre Pigmentepithelunregelmäßigkeiten bei einem 38-jährigen Patienten – „Akute retinale Pigmentepitheliitis“. Klin Monatsbl Augenheilkd. https://doi.org/10.1055/a-1241-4521CrossRefPubMed

26.

Gallego-Pinazo R, Dolz-Marco R, Gómez-Ulla F, Mrejen S, Freund KB (2014) Pachychoroid diseases of the macula. Med Hypothesis Discov Innov Ophthalmol 3:111115

27.

Lange C, Treumer F, Bertram B, Feltgen N, Hoerauf H, Pauleikhoff D, Roider J (2019) Stellungnahme des Berufsverbandes der Augenärzte Deutschlands, der Deutschen Ophthalmologischen Gesellschaft und der Retinologischen Gesellschaft zur Chorioretinopathia centralis serosa (CCS). Ophthalmologe 116:10–20

28.

Liegl R, Ulbig MW (2014) Central serous chorioretinopathy. Ophthalmologica 232:65–76PubMedCrossRef

29.

Baraki H, Feltgen N, Roider J, Hoerauf H, Klatt C (2010) Chorioretinopathia centralis serosa (CCS). Ophthalmologe 107:479–492PubMedCrossRef

30.

Garg SP, Dada T, Talwar D, Biswas NR (1997) Endogenous cortisol profile in patients with central serous chorioretinopathy. Br J Ophthalmol 81:962–964PubMedPubMedCentralCrossRef

31.

Eom Y, Oh J, Kim SW, Huh K (2012) Systemic factors associated with central serous chorioretinopathy in Koreans. Korean J Ophthalmol 26:260–264PubMedPubMedCentralCrossRef

32.

de Jong EK, Breukink MB, Schellevis RL, Bakker B, Mohr JK, Fauser S, Keunen JEE, Hoyng CB, den Hollander AI, Boon CJF (2015) Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology 122:562–570PubMedCrossRef

33.

Schubert C, Pryds A, Zeng S, Xie Y, Freund KB, Spaide RF, Merriam JC, Barbazetto I, Slakter JS, Chang S et al (2014) Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy. Hum Mutat 35:859–867PubMedPubMedCentralCrossRef

34.

Gass JD, Little H (1995) Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology 102:737–747PubMedCrossRef

35.

Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82–118PubMedCrossRef

36.

Yalcinbayir O, Gelisken O, Akova-Budak B, Ozkaya G, Gorkem Cevik S, Yucel AA (2014) Correlation of spectral domain optical coherence tomography findings and visual acuity in central serous chorioretinopathy. Retina 34:705–712PubMedCrossRef

37.

Bujarborua D, Nagpal PN, Deka M (2010) Smokestack leak in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 248:339–351PubMedCrossRef

38.

Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D (1994) Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 112:1057–1062PubMedCrossRef

39.

Iacono P, Battaglia PM, Papayannis A, La Spina C, Varano M, Bandello F (2015) Acute central serous chorioretinopathy: a correlation study between fundus autofluorescence and spectral-domain OCT. Graefes Arch Clin Exp Ophthalmol 253:1889–1897PubMedCrossRef

40.

Bonini Filho MA, de Carlo TE, Ferrara D et al (2015) Association of choroidal 642 neovascularization and central serous chorioretinopathy with optical coherence 643 tomography angiography. JAMA Ophthalmol 133:899–906PubMedCrossRef

41.

Lotery A, Sivaprasad S, O’Connell A, Harris RA, Culliford L, Ellis L, Cree A, Madhusudhan S, Behar-Cohen F, Chakravarthy U, Peto T (2020) Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet 395:294–303PubMedCrossRef

42.

Frankel D, Suffo S, Seitz B, Abdin AD (2020) Eplerenone for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol. https://doi.org/10.1177/1120672120952648CrossRef

43.

Bousquet E, Dhundass M, Lejoyeux R, Shinojima A, Krivosic V, Mrejen S, Gaudric A, Tadayoni R (2019) Predictive factors of response to mineralocorticoid receptor antagonists in nonresolving central serous chorioretinopathy. Am J Ophthalmol 198:80–87PubMedCrossRef

44.

Maier M, Stumpfe S, Feucht N, Strobl P, Rath V, Lohmann CP (2014) Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy. Ophthalmologe 111:173–180PubMedCrossRef

45.

Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, Mizota A, Yuzawa M (2015) One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 3:555–561CrossRef

46.

Funk S, Fulga R, Klabe K, Breyer D, Seitz B, Langenbucher A, Kaymak H (2021) Nanosecond laser treatment in chorioretinopathia centralis serosa without RPE defects: a retrospective case series. Klin Monatsbl Augenheilkd 238(1):60–66. https://doi.org/10.1055/a-0999-5542CrossRefPubMed

47.

Kaymak H, Funk S, Fricke A et al (2020) Efficacy of nanosecond laser treatment in central serous chorioretinopathy with and without atrophy of retinal pigment epithelium. Int J Retin Vitr 6:11CrossRef

48.

Akkaya S (2018) Spectrum of pachychoroid diseases. Int Ophthalmol 38:2239–2246PubMedCrossRef

49.

Pang CE, Freund KB (2015) Pachychoroid neovasculopathy. Retina 35:1–9PubMedCrossRef

50.

Schworm B, Luft N, Keidel LF et al (2020) Ranibizumab non-response in pachychoroid neovasculopathy: effects of switching to aflibercept. Sci Rep 10:8439PubMedPubMedCentralCrossRef

51.

Yannuzzi LA, Sorenson J, Spaide RF, Lipson B (1990) Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 10:1–8PubMedCrossRef

52.

Dansingani KK, Gal-Or O, Sadda SR, Yannuzzi LA, Freund KB (2018) Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of ‘expanded spectra’—a review. J Clin Exp Ophthalmol 46:189–200CrossRef

53.

Wong CW, Yanagi Y, Lee WK et al (2016) Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res 53:107–139PubMedCrossRef

54.

Lee WK, Baek J, Dansingani KK, Lee JH, Freund KB (2016) Choroidal morphology in eyes with polypoidal choroidal vasculopathy and normal or subnormal subfoveal choroidal thickness. Retina 36:73–82CrossRef

55.

Lin WY, Yang SC, Chen SJ, Tsai CL, Du SZ, Lim TH (2015) Automatic segmentation of polypoidal choroidal vasculopathy from indocyanine green angiography using spatial and temporal patterns. Transl Vis Sci Technol 4:7PubMedPubMedCentralCrossRef

56.

Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S (2014) Photodynamic therapy for central serous chorioretinopathy. Eye (Lond) 28:944–957CrossRef

57.

Padron-Perez N, Arias L, Rubio M et al (2018) Changes in choroidal thickness after intravitreal injection of anti-vascular endothelial growth factor in pachychoroid neovasculopathy. Invest Ophthalmol Vis Sci 59:1119–1124PubMedCrossRef

58.

Chung H, Byeon SH, Freund KB (2017) Focal choroidal excavation and its association with pachychoroid spectrum disorders: a review of the literature and multimodal imaging findings. Retina 37:199–221PubMedCrossRef

59.

Obata R, Takahashi H, Ueta T, Yuda K, Kure K, Yanagi Y (2013) Tomographic and angiographic characteristics of eyes with macular focal choroidal excavation. Retina 33:1201–1210PubMedCrossRef

60.

Hoogmartens C, Stanzel BV (2020) Akute makuläre Neuroretinopathie bei einer 13jährigen Patientin mit fokaler choroidaler Exkavation und Pachychoroid. Ophthalmologe 117:791–797PubMedCrossRef

61.

Phasukkijwatana N, Freund KB, Dolz-Marco R et al (2018) Peripapillary pachychoroid syndrome. Retina 9:1652–1667CrossRef

62.

Fung AT, Yannuzzi LA, Freund KB (2012) Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina 32:1829–1837PubMedCrossRef

63.

Ahuja RM, Downes SM, Stanga PE et al (2001) Polypoidal choroidal vasculopathy and central serous chorioretinopathy. Ophthalmology 108:1009–1010PubMedCrossRef

64.

Koh A, Ahuja R, Downes S, Bird A (1999) Polypoidal choroidal vasculopathy in patients with chronic central serous chorioretinopathy. Invest Ophthalmol Vis Sci 40:5958

65.

Perkins SL, Kim JE, Pollack JS, Merrill PT (2002) Clinical characteristics of central serous chorioretinopathy in women. Ophthalmology 109:262–266PubMedCrossRef

66.

Spaide RF (2020) The ambiguity of pachychoroid. Retina. https://doi.org/10.1097/IAE.0000000000003057CrossRefPubMedPubMedCentral

Titel: Einheitliche Klassifikation des pachychorioidalen Krankheitsspektrums
Publikationsdatum: 26.04.2021
Erschienen in: Die Ophthalmologie / Ausgabe 8/2021
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI: https://doi.org/10.1007/s00347-021-01379-4

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Einheitliche Klassifikation des pachychorioidalen Krankheitsspektrums

Zusammenfassung

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

Bestmögliche Wundheilung der Kornea dank optimaler pharmakologischer Therapie

Update Augenheilkunde

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2021

Augenheilkunde 3.0: Chancen auf eine bessere Patienteninformation

Idiopathische orbitale Entzündungen

IgG4-assoziierte Erkrankung

Spezifische orbitale Entzündungen

Pseudotumor orbitae

Kombination aus Dezentrierung und Verkippung der Linse im phaken und pseudophaken Auge – optische Simulation von Defokus, Astigmatismus und Coma

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

Bestmögliche Wundheilung der Kornea dank optimaler pharmakologischer Therapie

Update Augenheilkunde